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METHYLENE BLUE AS AN INHIBITOR OF SUPEROXIDE
GENERATION BY XANTHINE OXIDASE:
A POTENTIAL NEW DRUG FOR THE ATTENUATION OF
ISCHEMIA/REPERFUSION INJURY
STEVEN C. SALARIS, CHARLES F. BARBS, and WILLIAM D. VOORHEES III
Biomedical Engineering Center, and School of Veterinary Medicine, Purdue University, West
Lafayette, Indiana, USA.
[Biochemical Pharmacology, Vol. 42, No. 3, pp. 499-506, 1991]
ABSTRACT
Tissue oxidases, especially xanthine oxidase, have been proposed as primary sources of toxic
oxygen radicals in many experimental models of disease states. Among these, ischemiareperfusion injury may be of the greatest clinical interest. In this paper we propose the use of
methylene blue as a means of suppressing the production of superoxide radicals, O2, by acting
as an alternative electron acceptor for xanthine oxidase. Previous work has indicated that
methylene blue accepts electrons from xanthine oxidase at the iron-sulfur center. Initial
experiments in our laboratory demonstrated that (1) pairs of electrons from each enzymatic
oxidation are transferred to methylene blue, (2) the reduction of methylene blue can be achieved
by model iron-sulfur centers, similar to the iron-sulfur center of xanthine oxidase, (3) reduced
methylene blue auto-oxidizes to produce H2O2 directly, rather than O2, and (4) methylene blue
is effective at non-toxic levels (2-5 mg/kg) in preventing free radical damage to liver and kidney
tissues in an in vitro model of ischemia and reoxygenation. Accordingly, we propose that
methylene blue may represent a new class of antioxidant drugs that competitively inhibit
reduction of molecular oxygen to superoxide by acting as alternative electron acceptors for tissue
oxidases. We have termed these agents “parasitic” electron acceptors.
Key words: class, drug development, hydrogen peroxide, new, novel, oxidative stress, reactive
oxygen species, therapy
Abbreviations: DMSA, dimercaptosuccinic acid; HO, hydroxyl radical; HX, hypoxanthine;
LD50, median lethal dose; MDA-LM, malondialdehyde-like materials; NBT, nitroblue
tetrazolium; SOD, superoxide dismutase; and X, xanthine.
Supported by Grants HL-36712 and HL-35996 from the National Heart, Lung, and Blood Institute, U.S.
Public Health Service, Bethesda, Maryland, USA.
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INTRODUCTION
An increasing body of evidence implicates the involvement of oxygen-derived free radicals in
the pathophysiology of arthritis, iron toxicity, Parkinson’s disease, and a variety of disease states
including ischemia followed by reperfusion [l-4]. Superoxide (O2) is undoubtedly the most
abundant oxygen radical generated in vivo. Biological sources of superoxide include activated
leukocytes [5], the mitochondrial electron transport chain [6], and tissue oxidases, most notably
xanthine oxidase [7-9]. The current model of reperfusion injury [l, 7, 10, 11] states that during
the ischemic period, hypoxanthine and xanthine substrates accumulate due to the anaerobic
breakdown of ATP. At the same time, there is a measurable increase in the amount of xanthine
oxidase in the cell due to a proteolytic conversion of xanthine dehydrogenase to xanthine oxidase
[12, 13]. Upon reoxygenation, a burst of superoxide radicals may be formed in certain cell types
by the action of xanthine oxidase upon accumulated hypoxanthine and xanthine substrates [7].
In the presence of suitably chelated iron, a fraction of the superoxide generated by biological
sources may participate in the superoxide driven Fenton reaction, in which hydroxyl radical
(HO) formation occurs [4, 14, 15]:

where An is a chelator anion rendering iron soluble at physiological pH. Nascent hydroxyl
radicals, or perhaps intermediate oxo-iron complexes themselves [16, 17], can react with various
proteins, nucleic acids or lipids in the cell [4, 18, 19], initiating chains of uncontrolled free
radical reactions that may complicate circulatory shock, arterial thromboembolism, cardiac
arrest, and other clinical entities.
There are currently several methods under investigation to prevent or attenuate superoxide and
iron mediated injury. The first is the use of antioxidant enzymes such as superoxide dismutase
(SOD) and catalase which scavenge and break down superoxide and hydrogen peroxide,
respectively [20, 21]. Alternatively, iron chelating compounds such as deferoxamine may inhibit
superoxide-initiated injury, presumably by preventing the redox cycling of iron [22, 23]. Another
attractive approach may be the use of xanthine oxidase inhibitors [2, 24, 25]. Best known among
these inhibitors are the purine analogs, oxypurinol and allopurinol, which bind competitively to
the purine binding site of the enzyme, displacing hypoxanthine and xanthine.
However, another neglected approach to pharmacologic inhibition of O2  production by xanthine
oxidase exists. In 1988, Kelner et al. [26] re-examined the early work of McCord and Fridovich
[27] suggesting that methylene blue can act as a willing electron acceptor for xanthine oxidase,
an enzyme that allows for the anaerobic oxidation of purine substrates. They proposed that this
readily available and already clinically used compound might inhibit the production of
superoxide in postischemic tissues [26] by competing with molecular oxygen at the iron-sulfur
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centers of xanthine oxidase. Intrigued by Kelner’s thoughts and observations, we have begun to
study methylene blue as a possible inhibitor of O 2 production by xanthine oxidase.
In this paper, we present an elaboration of Kelner’s original idea concerning the mechanism of
action and pharmacology of methylene blue during oxidative stress. We propose that methylene
blue (and perhaps other related compounds) may attentuate the pathophysiology of reperfusion
injury by two methods: First, if given as a pretreatment (prior to ischemia), it may allow for the
anaerobic breakdown of hypoxanthine and xanthine to uric acid and thus attenuate the
accumulation of hypoxanthine during ischemia. Second, if given either before ischemia or just
before reperfusion, methylene blue may help prevent superoxide formation, since it competes
favorably with molecular oxygen for reduction by xanthine oxidase [28]. In this hypothetical
role, methylene blue does not act as a classical xanthine oxidase inhibitor, because it does not
slow the rate of oxidation of hypoxanthine or xanthine. Indeed, it appears to increase the rate of
such reactions in some studies [28]. Instead, methylene blue acts an inhibitor of oxygen
reduction, and may well function as such for other oxidases in addition to xanthine oxidase.
Routine use of methylene blue as a tissue stain leaves little doubt as to its ability to penetrate
intracellular as well as extracellular fluid compartments. Note however, that the doses required to
achieve the desired therapeutic effect are insufficient to render an animal or patient comically
blue in color (pseudocyanosis) and indeed are within the range currently recommended for use in
human medicine.
Biochemically, our working hypothesis is that methylene blue is reduced to the colorless leuko
form, as a result of the action of xanthine oxidase. In the presence of oxygen, the
leukomethylene blue then auto-oxidizes back to ordinary methylene blue with the concurrent
formation of hydrogen peroxide directly, rather than superoxide. The transfer of electrons in
pairs to methylene blue, rather than singly to oxygen, thus short-circuits the formation of
superoxide by the enzyme. Without superoxide, the reduction of Fe3+ to Fe+2 does not occur, and
even though hydrogen peroxide is formed, there is not sufficent Fe2+ to allow for either the
formation of damaging amounts of HO by Fenton’s reaction or the formation of ferrous-ferric
complexes capable of initiating lipid peroxidation in the absence of HO [16, 17]. The hydrogen
peroxide that is formed is then readily detoxified in vivo by the action of catalase and
peroxidases.
Regarding the products of auto-oxidation of leukomethylene blue, there appear to be two schools
of thought, one stating that leukomethylene blue auto-oxidizes to hydrogen peroxide [26, 29] and
another stating that leukomethylene blue can auto-oxidze univalently to superoxide [27].
Accordingly, we were especially interested in exploring the major products of leukomethylene
blue auto-oxidation. Significant univalent reduction of oxygen by leukomethylene blue to form
superoxide would obviate the use of methylene blue to suppress superoxide formation.
For these reasons, we gave serious consideration to the potential use of methylene blue as a drug
to suppress superoxide formation by xanthine oxidase and performed a number of simple
biochemical experiments to (1) explore the number of electrons transferred during methylene
blue reduction, (2) determine if model iron-sulfur centers could reduce methylene blue, (3)
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measure superoxide production during auto-oxidation of leukomethylene blue, and (4) test the
ability of methylene blue to suppress one indicator of oxygen radical injury in a tissue model of
ischemia and reperfusion.
METHODS AND RESULTS
Stoichiometry of methylene blue reduction
To further explore the antioxidant potential of methylene blue in the laboratory, we first studied
the stoichiometry of electron transfer from xanthine to methylene blue. Others have suggested
that for each oxidation step, either from hypoxanthine to xanthine or from xanthine to uric acid,
there are two electrons transferred to the enzyme [8, 30]. If, in turn, xanthine oxidase transfers
two electrons to methylene blue in each oxidation step, we expect 1 mole of leukomethylene blue
to be produced for each mole of xanthine oxidized to uric acid and 2 moles of leukomethylene
blue for each mole of hypoxanthine oxidized completely to uric acid.
To test this assertion, we performed some simple spectrophotometric studies. A reaction mixture
of 0.05 units/ml of xanthine oxidase was added to a 1.5-mL quartz spectrophotometric cuvet
containing 37.4 nmol of methylene blue, and 15 nmol of either xanthine or hypoxanthine in
argon-saturated (anoxic) Tris-Ringer buffer* at pH 7.4. The reaction vessel was suffused with
argon and covered to exclude oxygen. The conversion of methylene blue to leukomethylene blue
was recorded as a decrease in the absorbance of the solution at 667 nm. Based on the extinction
coefficient of methylene blue in Tris-buffer (4.9 x l04 M1 cm1, our value), the amount of
methylene blue reduced was calculated. Our measured coefficient is in good agreement with the
literature value (50,119 M1 cm1) [31]. The results (Table 1) indicated that xanthine oxidase
supplied with 15 nmol of xanthine reduced 14.6  0.3 nmol of methylene blue (mean  SEM)
and 15 nmol of hypoxanthine reduced 29.1  0.4 nmol of methylene blue (N = 10).
These observations confirm that the reduction of methylene blue is a 2-electron process as
previously indicated by Blaedel and Meloche [32]. This observation is important, because if
leukomethylene blue is a 2-electron reduction product of methylene blue, then it is reasonable to
expect that two electrons might also be transferred to molecular oxygen when methylene blue
auto-oxidizes, thus forming H2O2 rather than superoxide, as proposed previously by Kelner et al.
[26].

* The Tris-Ringer buffer solution included 4.0 mM KCl, 100 mM NaCl, 2.0 mM CaCl2, 40 mM
Tris, and 200 mg/dL glucose, pH 7.4. Tris was chosen as a buffer rather phosphate because of its
solubility in the presence of calcium.
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Table 1. Methylene blue reduction by xanthine oxidase under anaerobic conditions.
The substrate was either xanthine (X, 15 nmol) or hypoxanthine (HX, 15 nmol)

Reaction of model iron-sulfur centers with methylene blue
The reduction of methylene blue by xanthine oxidase occurs in both the molybdenum free and
deflavinated enzyme forms [33, 34]. Therefore, it has been suggested that the point of methylene
blue reduction must be at the iron-sulfur center [26]. The native xanthine oxidase enzyme
contains two iron-sulfur centers of the 2Fe-2S type [8, 35], having two iron atoms chelated by six
sulfur moieties (Fig. 1).
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Fig. 1. Cartoon-like sketch of xanthine oxidase, illustrating the proposed role of
methylene blue (MB) as a parasitic electron acceptor. The enzyme consists of two
subunits, each with purine binding sites, MoIV, iron-sulfur (Fe-S) centers, and a flavin
[8, 35-37]. The catalytic action is illustrated with molecular oxygen (left) and
methylene blue (right) serving as electron acceptors. In the normal sequence on the
left, electrons travel to the flavin to be transferred to oxygen, forming superoxide [36,
37]. The authors propose that in the presence of methylene blue, on the right, the
electrons are diverted to the dye at the iron-sulfur center. In this way, methylene blue
may act as a parasitic electron acceptor that inhibits production of O2.
To further explore this concept, we sought to determine if a reduced iron-sulfur center can, in
fact, reduce methylene blue. In simple aqueous solutions, ferrous iron alone did not reduce
methylene blue and neither did thiols. Hence, the juxtaposition of iron and sulfur atoms of the
iron-sulfur center must be critical. To model a reduced iron-sulfur center, we utilized the chelate
of Fe2+ and an excess of dimercaptosuccinic acid (DMSA) in dilute, anoxic (argon saturated)
solutions. The combination of these reagents caused an evident interaction between the ferrous
iron and the sulfur groups of DMSA, which formed a colored chelate that ranges from brown to
pink, depending on the relative concentrations of the two compounds, and was not formed upon
combination of ferrous iron with ordinary succinic acid. This model is less complex than the true
structure of the iron-sulfur center, but it still includes an Fe2+ surrounded by at least four sulfurs
(Fig. 2).
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Fig. 2. An idealized configuration of the DMSA-iron chelate. The Fe2+ is chelated by
the four sulfhydryl groups of two dimercaptosuccinic acid molecules. This complex
models the iron:sulfur ratio seen in the iron-sulfur centers of xanthine oxidase and
appears to mimic the iron-sulfur center of xanthine oxidase in that it is capable of
reducing methylene blue.
These experiments used 50 nmol/mL of Fe2+ chelated in the presence of 800 nmol/mL of DMSA.
At the above concentrations, the chelate formed was pink in color and exhibited an absorbance
peak at 360 nm. DMSA (from Aldrich) and 50 nmol of FeSO 4 were added to argon-saturated
(anoxic) Tris-Ringer buffer (1.0 mL, pH 7.4), after which 15 nmol of methylene blue was added.
In N = 6 trials, the absorbance of the methylene blue (667 nm) was seen to decrease after only 3
min (Fig. 3). The cuvet was then reoxygenated by gently bubbling with 100% O2 to promote the
auto-oxidation of leukomethylene blue with return of the original color. DMSA-only and Fe2+only controls did not reduce methylene blue (N = 3). These simple experiments are consistent
with the hypothesis that reduced iron-sulfur centers, similar to those in xanthine oxidase, can, in
fact, reduce methylene blue.
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Fig. 3. Typical visible spectra illustrating methylene blue reduction in the presence of
the model iron-sulfur (Fe-S) center. (1) A 6  M concentration of methylene blue (MB)
showed characteristic absorbance peak at 667 nm. (2) After 3 min, the methylene blue
absorbance peak was reduced anaerobically in the presence of the model Fe-S centers
(50  M FeSO4 + 800  M DMSA). (3) When this mixture was reoxygenated, the
leukomethylene blue auto-oxidized and the original blue color returned. (4) The
spectrum of the chelate alone is included for comparison. Spectra were manually
digitized for plotting. FeSO4 alone and DMSA alone did not reduce methylene blue
(data not shown).

8

Auto-oxidation of leukomethylene blue
To more directly test the hypothesis that methylene blue auto-oxidation yields H2O2 rather than
O2, we compared auto-oxidation of Fe2+-citrate with that of leukomethylene blue. Ferrouscitrate is expected to auto-oxidize via a single electron transfer, Fe2+-citrate + O2  Fe3+-citrate
+ O2) thus providing a positive control. Fe2+-citrate (500 M) was added to an O2 bubbled
solution of pH 7.4 Tris buffer. To detect O2 , nitroblue tetrazolium (NBT, 500 M) was added at
0, 15, 30, 45, 60, or 90 sec after Fe2+-citrate oxidation had begun and allowed to react for 3 min
at room temperature. In the presence of O2 NBT is reduced to a purple diformazan, which can
be extracted into toluene and measured spectrophotometrically [38]. This approach was selected
as an alternative to cytochrome-c reduction for the present application, because the leuko-dyes as
well as O2, are known to reduce cytochrome-c [27].
In a similar fashion, methylene blue (250 M) was reduced to leukomethylene blue by addition
of equimolar amounts of sodium hydrosulfite at pH 7.4. The solution was then reoxygenated
until the blue color completely returned (approximately 10 sec), after which NBT was added at
similar times as above. In some experiments, the NBT was added into the leukomethylene blue
at time 0 and the solution then reoxygenated. Parallel control experiments were performed in the
presence of 2 mg/mL (6000 units/ml) superoxide dismutase from Sigma (N = 3).
The reduced NBT from the auto-oxidation experiments was then extracted into 3 vol. of toluene
and read in a spectrophotometer ( max = 595 nm) against a toluene blank. Based on the extinction
coefficient of reduced NBT in toluene (our value 5.36 x 104 M1 cm1), the concentration of
reduced NBT was calculated by Beer’s Law. Results of such time course experiments comparing
auto-oxidation of Fe2+-citrate and leukomethylene blue are shown in Fig. 4.
The left panel of Fig. 4 illustrates the SOD inhibitable reduction of NBT following autooxidation of Fe2+-citrate during the first 150 sec. The decrease in colored diformazan formation
with later addition of NBT reflects the spontaneous dismutation of O2 to H2 O2. In comparison,
the right panel of Fig. 4 shows negligible amounts of SOD inhibitable NBT reduction following
auto-oxidation of leukomethylene blue during the first 150 sec. NBT reduction at time 0 is
attributable to the direct action of leukomethylene blue in the absence of oxygen, which was not
SOD inhibitable. These observations are consistent with the hypothesis that molecular oxygen
reacting with leukomethylene blue in buffered, neutral aqueous solution is not reduced to
superoxide, but probably undergoes a direct 2-electron reduction to H2O2 .
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Fig. 4. Left panel: Appearance of SOD inhibitable NBT reducing equivalents after
auto-oxidation of 500  M Fe2+-citrate in pH 7.4 Tris buffer. Auto-oxidation began at
time zero. NBT (500  M) was added at the times indicated, and reduced NBT was
recovered by toluene extraction and measured spectrophotometrically. The NBT
reducing equivalents detected decayed exponentially over time as would be expected for
superoxide undergoing spontaneous dismutation. Addition of Sigma SOD (6000
units/mL) completely quenched NBT reduction by this system. This experiment
constitutes a positive control since auto-oxidation of ferrous iron chelates is well
known to produce superoxide. Values are means  SEM for N = 3. Right panel:
Appearance of NBT reducing equivalents after auto-oxidation of leukomethylene blue.
This series of experiments was similar to the series in the left panel. Leukomethylene
blue was produced by the addition of 250  M sodium hydrosulfite to an equimolar
amount of methylene blue under anaerobic conditions. The solution was then bubbled
with 100% oxygen to initiate auto-oxidation of leukomethylene blue. NBT (500  M)
was added at the times indicated, and reduced NBT, recovered by toluene extraction,
was measured spectrophotometrically. When NBT was added directly to
leukomethylene blue, there was reduction of NBT before addition of oxygen that was
not SOD inhibitable. There was no SOD inhibitable NBT reduction after oxidation.
Values are means  SEM for N = 3.
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Inhibition of reoxygenation injury in tissue slices
To test the ability of methylene blue to quench free radical formation in ischemia/reperfusion, we
employed a previously described model of ischemia and reoxygenation [39, 40] in vitro, in
which free floating liver or kidney slices were exposed to 60 min of ischemia in argon-saturated
(anoxic) buffer before being treated with methylene blue at final concentrations of 0, 1, 2, 5, 10
or 25 g/mL (mg/kg) 10 min prior to reoxygenation. The tissues were then reoxygenated in
100% O2 saturated buffer for 60 min, after which the tissues and buffer were assayed, using the
thiobarbituric acid reaction [41] for malondialdehyde-like materials (MDA-LM), which are
indicators of free radical mediated lipid peroxidation. The results (Figs. 5 and 6) show that
significant production of MDA-LM occurred at zero or low concentrations of methylene blue.
However, significant concentration-related attenuation of MDA-LM generation occurred for both
tissues.

Fig. 5. Postischemic MDA-LM production, an indicator of lipid peroxidation, in rat
kidney slices in the presence of various concentrations of methylene blue. Methylene
blue was added 10 min prior to reoxygenation of tissues that were ischemic for 1 hr
total. Reoxygenation was with 100% oxygen gas. Mean productions of MDA-like
materials measured by the thiobarbituric acid method are shown  SEM. An asterisk
(*) indicates significance vs. untreated controls at  = 0.05 by Scheffe’s multiple
comparison est. Values are means  SEM for N = 6.
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Fig. 6. Postischemic MDA-LM production, an indicator of lipid peroxidation, in rat
liver slices in the presence of various concentrations of methylene blue. Methylene blue
was added 10 min prior to reoxygenation of tissues that were ischemic for 1 hr total.
Reoxygenation was with 100% oxygen gas. Mean productions of MDA-like materials
measured by the thiobarbituric acid method are shown  SEM. An asterisk (*)
indicates significance vs. untreated controls at  = 0.05 by Scheffe’s multiple
comparison est. Values are means  SEM for N = 6.
Methylene blue alone did not inhibit the thiobarbituric acid reaction, as was determined by
adding various methylene blue concentrations to MDA standards and observing no inhibition of
reaction product formation. These data confirm those previously published [39] and suggest that
clinically realistic doses (5 mg/kg) of methylene blue can protect against oxygen radical
mediated injury of postischemic tissues.
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DISCUSSION
The foregoing simple experiments support the claim that methylene blue may well be an
effective antioxidant in the setting of ischemia/reperfusion injury when administered in clinically
realistic concentrations prior to the return of molecular oxygen. Methylene blue, together with
other related compounds such as celestine blue, toluidine blue O, thionin, and azure A, which are
also reduced to leuko forms by xanthine oxidase (unpublished observations) [42], may constitute
a new class of antioxidant drugs that act by suppressing O2 formation by tissue oxidases. In
contrast to classical purine analog type xanthine oxidase inhibitors. these agents would not
inhibit hypoxanthine and xanthine conversion to uric acid, but would selectively inhibit O2
formation by serving as competitive, alternative co-substrates.
Such alternative electron acceptors seem to be characterized by their apparent ability to accept
two electrons, rather than one electron, and, in turn, auto-oxidizing to form H2O2 directly rather
than O2. That is

rather than

.
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The high affinity of methylene blue for the iron-sulfur center of xanthine oxidase [28] favors the
former over the latter sequence, even in the presence of 100% O 2 during reoxygenation. In this
sense, we argue that methylene blue acts as a “parasitic” electron acceptor, shunting electron
flow from the normal pathway within the enzyme to form leukomethylene blue at the level of the
iron-sulfur centers (Fig. 1, right). The drug effectively short-circuits O 2 generation since the
electron flow through the enzyme is preferentially routed to methylene blue at the iron-sulfur
center rather than to molecular oxygen at the flavin centers. In turn, redox cycling of low
molecular weight chelate iron in the superoxide driven Fenton reaction is avoided, because there
is no superoxide to reduce Fe3+ to Fe2+.
Although earlier work by McCord and Fridovich [27] indicated that reduced methylene blue was
capable of univalently reducing oxygen to superoxide, the detection method used (adenochrome
formation) indicated that the rate of superoxide formation was relatively slow. The present
results clearly indicate that the formation of hydrogen peroxide, rather than superoxide, is the
dominant product of leukomethylene blue auto-oxidation, compared to ferrous citrate autooxidation, in which abundant superoxide is formed. The end result, prevention of O2 generation,
is similar to the effect of SOD. However, unlike SOD, methylene blue, which is a low molecular
weight, partially liposoluble agent, is unquestionably able to penetrate cells and tissues, in view
of its use as a rapidly penetrating histological stain. These properties may make methylene blue
an especially useful pharmacologic agent, which has already been proven safe at likely effective
doses in human patients.
Methylene blue is currently used in medicine for the treatment of cyanide poisoning,
methemoglobinemia, nitrite poisoning, and urinary tract infections [43-47]. In a guinea pig
model of nitrite toxicosis, 10 mg/kg of methylene blue protected against methemoglobinemia
following a 50 mg/kg dose of NaNO2 [47]. As early as 1935, methylene blue was used as a
treatment for urinary tuberculosis [44]. The treated human patients showed post-operative weight
increase and relief of symptoms in 11 of 12 cases with unilateral renal tuberculosis. In the case of
methemoglobinemia in the adult human, methylene blue is given as an injection of 50 mL of a
1% solution. The dye then acts therapeutically to accelerate reductive processes in the cell. It is
effective in cases of NADPH-methemoglobin reductase deficiency but not in cases of
methemoglobinemia due to glucose-6-phosphate dehydrogenase deficiency [46, 48]. It is also a
relatively non-toxic compound and can be used over a wide range of doses. In humans with
cyanide poisoning, a 500 mg bolus is given, which corresponds to a dose of approximately 7
mg/kg [49]. In the dog and rat, the LD50 values (median lethal dose) for i.v. methylene blue are
50 and 1250 mg/kg, respectively. In monkeys, the lowest published toxic dose is 10 mg/kg [50].
The action of methylene blue and similar drugs as parasitic electron acceptors opens up a variety
of therapeutic possibilities. As a pretreatment, as in cases of aortic cross-clamping or organ
transplantation, methylene blue might be given just prior to the ischemic period to provide a
substrate for the anaerobic breakdown of hypoxanthine and xanthine. In conditions such as
circulatory shock, arterial thromboembolism, or bowel torsion with strangulation, methylene
blue could be given as a post-treatment (i.e. after the onset of ischemia) and still be effective,
since the competition kinetics favor the reduction of methylene blue rather than molecular
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oxygen [28]. The low-toxicity, effectiveness, and unique biochemistry of methylene blue and its
congeners, may make such compounds valuable in the future study and treatment of tissue injury
thought to be mediated by xanthine oxidase and superoxide.
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